Compare CRDL & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | MITT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 245.5M |
| IPO Year | 2017 | 2011 |
| Metric | CRDL | MITT |
|---|---|---|
| Price | $1.15 | $5.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $8.42 | ★ $8.71 |
| AVG Volume (30 Days) | ★ 1.5M | 423.9K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 17.52% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.69 |
| P/E Ratio | ★ N/A | $547.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $5.39 |
| 52 Week High | $2.34 | $9.27 |
| Indicator | CRDL | MITT |
|---|---|---|
| Relative Strength Index (RSI) | 21.71 | 25.85 |
| Support Level | $0.96 | N/A |
| Resistance Level | $1.35 | $8.00 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 1.64 | 10.59 |
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.